Testosterone and fertility: The trade-off and the approaches used to address it

Introduction: A trade-off worth understanding before you start

Here's a situation that comes up regularly in men's health. A man in his early thirties has symptoms of low testosterone, starts testosterone replacement therapy, and feels better. A couple of years later he and his partner decide to try for a child, and a semen analysis comes back showing a very low sperm count.

This is not an unusual side effect. It's the expected physiological consequence of supplying testosterone from outside the body, and it's worth understanding before starting rather than after. This article explains the mechanism and the approaches used to address it. It's educational, not medical advice, and not a promise about any individual's fertility.

Why exogenous testosterone suppresses fertility

The hormonal system runs on feedback. The hypothalamus produces GnRH, which prompts the pituitary to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH signals the testes to produce testosterone; FSH supports sperm production. When testosterone is sufficient, the hypothalamus reduces GnRH output.

When testosterone is supplied from outside, blood levels rise, the hypothalamus detects this and reduces GnRH, and the pituitary produces less LH and FSH. With reduced FSH, the Sertoli cells that support sperm development lose their stimulation, and sperm production declines substantially.

This is the expected response to exogenous testosterone, not a rare complication. How much it affects any individual, and how fully production recovers after stopping, varies.

Approach one: Enclomiphene on its own

For men whose priority is maintaining fertility while addressing low testosterone, enclomiphene works differently. By blocking estrogen feedback at the hypothalamus, it increases GnRH, LH, and FSH, supporting the body's own testosterone production rather than replacing it, and it doesn't introduce testosterone from outside.

This approach is often discussed for men who are trying to conceive or expect to, men with a signaling-level shortfall, and men who prefer to try a more conservative option first. Its limitation is that it depends on the testes being able to respond to increased stimulation, so it may not be sufficient for everyone. Enclomiphene is a compounded medication and is not FDA-approved.

Approach two: Testosterone therapy alongside gonadorelin

For men who need the more direct effect of testosterone therapy, gonadorelin may be used alongside it. Gonadorelin provides GnRH signaling to the pituitary, supporting LH and FSH output that exogenous testosterone otherwise suppresses. It's used for HPG axis support, endogenous testosterone support, and fertility preservation.

This is a more involved protocol to manage, and whether it's appropriate is a clinical decision made with a provider. Gonadorelin is a compounded medication and is not FDA-approved.

Approach three: Combined protocols

Some protocols involve more than two of these medications, with testosterone providing the direct effect, gonadorelin supporting pituitary and testicular signaling, and enclomiphene adding hypothalamic-level stimulation and influencing estrogen feedback.

We'd note that more medications is not automatically better. Whether a combined approach is appropriate depends on your health history, your fertility intentions, and a provider's assessment.

Raising it early

The practical takeaway is simple: if fertility matters to you now or might later, say so at the first conversation, before anything is prescribed. It's much easier to plan around than to reverse.

Assessing testosterone and fertility involves blood testing and, where relevant, semen analysis, interpreted by a clinician. Luvo's evaluation is based on your health history and reported symptoms; Luvo does not provide lab testing or semen analysis, so any testing is arranged through a licensed provider or your own physician.

Explore Luvo's Testosterone Program, or the individual options: testosterone, enclomiphene, and gonadorelin.